对于大多数多发性骨髓瘤患者而言，CD52并非一个有前景的免疫治疗靶点。

CD52 is not a promising immunotherapy target for most patients with multiple myeloma.

作者信息

Westermann Jörg, Maschmeyer Georg, van Lessen Antje, Dörken Bernd, Pezzutto Antonio

机构信息

Department of Hematology and Oncology, Charité University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany.

出版信息

Int J Hematol. 2005 Oct;82(3):248-50. doi: 10.1532/IJH97.E0435.

DOI:10.1532/IJH97.E0435

PMID:16207599

Abstract

The aim of our study was to evaluate CD52 as a target molecule for antibody therapy for multiple myeloma. Twenty consecutive bone marrow samples from myeloma patients were studied by flow cytometry using antibodies against CD45, CD38, CD138, CD3, CD19, and CD52. Most myeloma cells did not express CD52; CD52 expression was found only in a small subpopulation of plasma cells with a CD45+CD38++ phenotype. In contrast, the major fraction of myeloma cells (CD45-CD38++) was CD52-. Treatment of myeloma patients with anti-CD52 antibodies with the aim to reduce the number of myeloma cells in the CD45+CD38++ subfraction, which possibly contains a proliferative progenitor cell pool, would be at best a highly experimental approach. We conclude that CD52 is not a promising target for antibody-based therapies for most patients with multiple myeloma.

摘要

我们研究的目的是评估CD52作为多发性骨髓瘤抗体治疗的靶分子。使用抗CD45、CD38、CD138、CD3、CD19和CD52抗体，通过流式细胞术对20例连续的骨髓瘤患者骨髓样本进行研究。大多数骨髓瘤细胞不表达CD52；仅在一小部分具有CD45+CD38++表型的浆细胞中发现CD52表达。相反，骨髓瘤细胞的主要部分（CD45-CD38++）为CD52阴性。旨在减少CD45+CD38++亚群中骨髓瘤细胞数量（该亚群可能包含增殖祖细胞池）的抗CD52抗体治疗骨髓瘤患者，充其量只是一种高度实验性的方法。我们得出结论，对于大多数多发性骨髓瘤患者，CD52不是基于抗体治疗的有前景的靶标。